Supplementary Table S1. Patients' demography

	Number	Ob	Ob+DM	DM	Male	Female	BP (before)	BP (after)
Candesartan	14	9	5	0	9	5	162 ± 4/96 ± 2	145 ± 3/87 ± 3
Olmesartan	7	6	1	0	3	4	153 ± 7/94 ± 4	138 ± 2/81 ± 2
Telmisartan	5	0	3	2	3	2	155 ± 8/78 ± 5	144 ± 6/70 ± 5
Total	26	15	9	2	15	11	158 ± 3/92 ± 2	$143 \pm 2^{a}/82 \pm 2^{a}$

Ob, obesity alone; DM, diabetes alone; Ob+DM, obesity plus diabetes. BP, blood pressure before and 3 months after angiotensin receptor blocker administration (mmHg). ^aP < 0.001 comparing before vs after.

Supplementary Table S2. Alteration of urinary Ngal (uNgal) and albumin (uAlb) levels after treatment with angiotensin receptor blocker (ARB)

	uNgal/Cr	(μg/gCr)		uAlb/Cr (mg/gCr)		
	before ARB	after ARB		before ARB	after ARB	
Healthy control (n = 10)	8.6 ± 2.0			33 ± 9		
Normoalbuminuria (n = 14)	17.9 ± 4.2	11.1 ± 3.0		11.5 ± 2.3	9.9 ± 2.9	
Microalbuminuria (n = 6)	15.7 ± 8.3	13.0 ± 7.3		91 ± 31	48 ± 24	
Macroalbuminuria (n = 6)	23.0 ± 6.1	12.0 ± 3.4		688 ± 158	364 ± 126	
Total (n = 26)	18.5 ± 3.2	11.8 ± 2.3	<i>P</i> < 0.05	185 ± 65	100 ± 40	P < 0.01

Patients were subdivided according to the extent of albuminuria. When geometric means (instead of means) were compared after log transformation for urinary ratios of Ngal/Cr and Albumin/Cr, they were again significantly reduced after the treatment (n = 26, P < 0.05, respectively).